atezolizumab
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
atezolizumab
May 18, 2024, 01:12 |
Opinion
Results from the IMpassion132 trial presented at ESMO Breast 24
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “Results from the IMpassion132 trial presented…
May 16, 2024, 16:51 |
Insight
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
In the fast-growing field of oncology, we are witnessing significant advances in several treatment modalities…
May 13, 2024, 14:29 |
Insight
Jarushka Naidoo: A step forward in implementing anti-PD(L)1 across growing not otherwise specified of indications?
Jarushka Naidoo shared on X: "Ph III IMscin001 trial of Subcutaneous (sc) vs IV Atezolizumab…
May 12, 2024, 13:31 |
Blog
Stephen Liu: Update from phase 3 IMscin001 trial JTO and JTO CRR
Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter: “Update from…
Mar 18, 2024, 19:11 |
Blog
Fredrick Chite Asirwa: International Cancer Institute clinic is recruiting breast cancer patients for clinical trials currently
Fredrick Chite Asirwa, CEO/Executive Director of International Cancer Institute, posted on LinkedIn: "To contribute to…
Mar 4, 2024, 17:07 |
Drugs
George Mellgard: We delve into the complexities of FDA Accelerated Approvals in oncology using lessons from 16 withdrawn accelerated approvals in the past decade
George Mellgard, Medical Student at Columbia University Irving Medical Center in NYC, shared on X/Twitter:…
Jan 30, 2024, 19:29 |
Blog
Vrouyr Bilemjian: We have developed a tumor targeting drug delivery systems
Vrouyr Bilemjian, Solutions and Strategy Consultant at Innoplexus, made the following post on LinkedIn: "Excited…
Jan 16, 2024, 05:48 |
Drugs
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center,…
Dec 12, 2023, 17:44 |
Insight
Piotr Wysocki: SABCS2023 - Adjuvant chemoimmunotherapy does not benefit TNBC patients
Piotr Wysocki, Head of Department of Oncology at Jagiellonian University Hospital, shared on LinkedIn: "SABCS2023…
Nov 21, 2023, 02:13 |
Blog
Salah-Eddin Al-Batran: Our group is happy to announce the publication of the IKF-633/DANTE trial (phase 2 portion) in Journal of Clinical Oncology
Salah-Eddin Al-Batran, Director of IKF-The Frankfurt Institute of Clinical Cancer Research, shared on LinkedIn: "Dear…
1
2
All:
14
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube